Third Arc Bio

Immunology & Inflammation Therapeutics · Oncology Therapeutics
$72.5Mlatest round · Venture round · Jul 2024 · 2 yr ago
2backers · Andreessen Horowitz, Omega Funds
200+team · employees, estimated range
2021founded

Overview

Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.

Funding and backers

Total raised
$72.5M
1 round on record
Latest round
$72.5M
Venture round · Jul 2024 · 2 yr ago
Team
201-500
employees, estimated range
Backers
2
Andreessen Horowitz, Omega Funds
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 16, 2024 Raised a round Venture round $72.5M · SEC Form D 2021 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jul 2024 $72.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Third Arc Bio, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Joseph ErhardtExecutive OfficerSEC Form D
Peter LebowitzExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Andreessen Horowitz fund Omega Funds fund
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Ditto Bio
GV
backs Oblenio Bio
NEA
backs 858 Therapeutics
RA Capital Management
backs Synolo
Foresite Capital
backs Cullinan Therapeutics
Multimodal Ventures
backs Ditto Bio
Similar startupsby what they do, their industry and backers
Cullinan Therapeutics
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
Ditto Bio11-50 employees
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Valora TherapeuticsSeed $30M · 23 mo ago · Founded 2023 · 11-50 employees
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy…
ImmuneSensor TherapeuticsVenture round $10M · 3 yr ago · Founded 2019 · 51-200 employees
ImmuneSensor Therapeutics | Harnessing the innate immune system to treat inflammation, autoimmune disease and cancer.
Boomerang MedicalSeries B $20M · 14 mo ago · 51-200 employees
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
SynoloFounded 2023 · 1-10 employees
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.

Financials

Total raised
$72.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $72.5M Details

People

Joseph Erhardt
Executive Officer
SEC Form D
Peter Lebowitz
Executive Officer, Director
SEC Form D
Arjun Goyal
Director
SEC Form D
Otello Stampacchia
Director
SEC Form D
Francesco Draetta
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors2
Omega FundsVia a fund
160 portfolio companies: Windward Bio, Xiimedical, Xtuit and 157 more
Andreessen HorowitzVia a fund
857 portfolio companies
Report a mistake